Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Story’s next chapter begins

REG1VExtensive research2019-10-22 08:53
Mikael RautanenCEO
Discuss
Download report (PDF)

Revenio’s investor story remains interesting, as the strategy’s next phase begins after the acquisition of CenterVue. The core business continues to grow very profitably, the underlying market has strong structural growth drivers, and the products have exceptionally strong competitive advantages. Revenio has also shown over the years how capable they are in value creation through investments into product development, structural transitions, and long-term growth development projects.

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as software solutions under the iCare brand. In 2023, the Group’s net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Read more on company page

Key Estimate Figures2019-10-01

201819e20e
Revenue30.750.167.0
growth-%14.6 %63.4 %33.8 %
EBIT (adj.)10.214.321.2
EBIT-% (adj.)33.3 %28.5 %31.6 %
EPS (adj.)0.340.470.63
Dividend0.280.340.44
Dividend %2.2 %2.3 %3.0 %
P/E (adj.)36.931.323.6
EV/EBITDA27.134.017.7

Forum discussions

So stories change. Nowadays, there is a strong belief in efficient markets, and every single thing is “priced in”. Benjamin Graham used to talk...
7 hours ago
by Ummon
20
Fun to see such high activity in this thread! Feels like an appropriate place to mention that, with Revenio set to release its Q2 report next...
8 hours ago
by Oscar Matheson
5
In my opinion, in the case of Revenio, one can ask whether even the top management believes in that acquisition since they aren’t buying shares...
20 hours ago
by Mamma94
7
Revenio’s earnings have indeed fallen in 2023, 2024, and 2025. Sure, there have been headwinds from the dollar and such, but the “star stock...
yesterday
by äspee
11
I find the overall development of Revenio quite interesting, to be honest. Previously, Revenio was seen as such a reliable cash-flow machine...
8/22/2026, 2:54 PM
by Johannes Sippola
28
Actually, you already answered it yourself, but I see the acquisition specifically as the biggest risk. If for one reason or another the anticipated...
8/22/2026, 2:45 PM
by Turnipsi
1
Revenio’s share price has started to head upward again over the last few weeks. The shock following the acquisition has faded. Unfortunately...
8/21/2026, 7:34 PM
by SoftaSijoittaja
11